H.C. Wainwright raised the firm’s price target on Relay Therapeutics to $19 from $18 and keeps a Buy rating on the shares. The firm says RLY-2608 plus Faslodex “now commands a respectable efficacy profile.” The results last week compare favorably to the anticipated comparator in the pivotal context, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics 28.6M share Secondary priced at $7.00
- Relay Therapeutics Announces Pricing of Public Offering of Common Stock
- Oracle reports Q1 beat, EU says Apple must pay: Morning Buzz
- Alphabet, Meta initiated: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 9/10/2024, According to Top Analysts